Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWight, Joel C-
dc.contributor.authorHamad, N-
dc.contributor.authorCampbell, B A-
dc.contributor.authorKu, M-
dc.contributor.authorLee, K-
dc.contributor.authorRose, H-
dc.contributor.authorArmytage, T-
dc.contributor.authorLatimer, M-
dc.contributor.authorLee, H P-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorDickinson, M-
dc.contributor.authorKhor, Richard-
dc.contributor.authorVerner, E-
dc.identifier.citationInternal Medicine Journal 2021; online first: 16 Septemberen
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved.en
dc.titleDiffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance.en
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternal Medicine Journalen
dc.identifier.affiliationDepartment of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australiaen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationJames Cook University, Townsville, Australiaen
dc.identifier.affiliationSchool of Medicine, University of Sydney, Sydney, New South Wales, Australiaen
dc.identifier.affiliationAnatomical Pathology Department, NSW Health Pathology, Concord Repatriation General Hospital, Sydney, New South Wales, Australiaen
dc.identifier.affiliationCanberra Hospital, Canberra, Australiaen
dc.identifier.affiliationAustralian National University, Canberra, Australiaen
dc.identifier.affiliationFlinders Medical Centre, Adelaide, Australiaen
dc.identifier.affiliationSt Vincent's Hospital, Melbourne, Victoriaen
dc.identifier.affiliationDepartment of Haematology, Peter MacCallum Cancer Centre, Parkville, Victoriaen
dc.identifier.affiliationSchool of Medicine, Deakin University Geelong, Victoriaen
dc.identifier.affiliationDepartment of Clinical Pathology, University of Melbourne, Parkville, Victoriaen
dc.identifier.affiliationDepartment of haematology, Gosford Hospital, Gosford, New South, UKen
dc.identifier.affiliationSt Vincent's Clinical School, Sydney, University of New South UKen
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital Sydney, Australiaen
dc.identifier.affiliationSchool of Medicine, Sydney, University of Notre Dame Australiaen
dc.identifier.affiliationDepartment of Radiation oncology, Peter MacCallum Cancer Centre, Parkville, Victoriaen
dc.identifier.affiliationUniversity Hospital Geelong, Victoriaen
dc.identifier.affiliationThe University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationTownsville University Hospital, Townsville, Australiaen
dc.identifier.pubmedid34532916, Richard
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications- Haematology- Newton-John Cancer Wellness and Research Centre- Imaging and Therapy- Haematology- Newton-John Cancer Wellness and Research Centre- Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.